Effectiveness of a Blended Care Parenting Intervention for Parents With PTSD (KopOpOuders-PTSD)

January 31, 2024 updated by: Arkin

KopOpOuders-PTSD: Randomized Controlled Trial of A Preventive Blended Care Parenting Intervention for Parents With PTSD

KopOpOuders-PTSD is a new preventive blended care intervention for parents with PTSD. The purpose of this study is to evaluate its effectiveness in improving parenting and preventing child mental health problems.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Rationale: Children of parents with post-traumatic stress disorder (PTSD) are at increased risk of mental health problems, such as depression, anxiety and hyperactivity. They are also more likely than children of healthy parents to be exposed to potential trauma, especially in the family setting (e.g., child maltreatment). Parents with PTSD often experience difficulties in their parenting role (e.g., deficits in effective parenting, sense of parenting incompetence, lack of social support). Research in other mental disorders shows that preventively supporting parents with mental illness in their parenting role decreases mental health problems in children. As of yet, no preventive intervention specifically aimed at parents with PTSD exist. We have therefore adapted an existing preventive online course for parents with mental illness, 'KopOpOuders zelfhulp', into a blended care intervention for parents with PTSD: 'KopOpOuders-PTSD'. This intervention was developed in co-creation with parents with PTSD and their partners.

Objective: Main objective: to test the effectiveness of KopOpOuders-PTSD on macro- and micro-level parenting behavior. Secondary objectives: to test the effectiveness of KopOpOuders-PTSD on perceived parenting competence, parents' social support, and child mental health; to test whether intervention effects are moderated by baseline PTSD symptoms.

Study design: The study uses a single-blind randomized controlled trial design with three measurement points (pretest, posttest, and follow-up). Data are collected through self-report questionnaires (macro-level) and ecological momentary assessment (EMA; micro-level) using a smartphone app.

Study population: 142 adults (71 per condition) receiving PTSD treatment at Arkin (departments Sinai Centrum, NPI, Jellinek, Arkin Basis GGZ), who have parenting responsibilities for one or more children aged 4-17.

Intervention (if applicable): The intervention group receives KopOpOuders-PTSD, consisting of 5 online modules and 3 face-to-face sessions, in addition to treatment as usual. The control group does not receive intervention apart from treatment as usual, but can access the online modules of KopOpOuders-PTSD after participation.

Main study parameters/endpoints: Main study parameters are mean level change from pretest to posttest in parenting behavior at the macro- and micro-level.

Study Type

Interventional

Enrollment (Estimated)

142

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Amstelveen, Netherlands, 1186 AM
        • Recruiting
        • Sinai Centrum
        • Contact:
        • Principal Investigator:
          • Kathleen Thomaes
        • Sub-Investigator:
          • Matthijs Blankers
        • Sub-Investigator:
          • Catrin Finkenauer
        • Sub-Investigator:
          • Anouk De Gee
        • Sub-Investigator:
          • Jeannet Kramer

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Has current DSM-5 diagnosis of PTSD;
  • Is receiving PTSD treatment of at least three sessions at one of the following Arkin departments: Sinai Centrum, Jellinek, Punt P, NPI, or Arkin BasisGGZ;
  • Has parenting responsibilities for at least one child aged 4-17 (biological or legal relationship not required).

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Has urgent care needs or (imminent) crisis (e.g. current psychosis, substance detoxification, active suicidality);
  • Is not in contact with children (e.g. due to out of home placement);
  • Is receiving another form of parenting intervention during the participation period;
  • Severe psychological problems or intellectual disability (IQ < 50) are present in children (diagnosis of oppositional-defiant disorder, conduct disorder, psychotic spectrum disorder or personality disorder);
  • Inability to participate in the intervention and/or assessments (e.g., because of intellectual disability (IQ < 75), illiteracy, or insufficient mastery of the Dutch language).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention: KopOpOuders-PTSD
KopOpOuders-PTSD is a blended care (i.e., partially online and partially in person) intervention that addresses the enhancing of protective factors within the family setting (reducing negative parental self-perceptions; parent-child interaction quality, social support, child adaptive functioning/coping, and child understanding of the parent's illness) from a combination of transdiagnostic and PTSD-specific perspectives. It consists of 8 sessions (5 online self-help modules, 3 in-person sessions with a professional) to be completed in a maximum period of 9 weeks.
See arm description
Other Names:
  • KopOpOuders for PTSD
No Intervention: Control: No intervention
The control group receives no parenting intervention during their participation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Alabama Parenting Questionnaire (APQ)
Time Frame: 2 months
Parenting skills are measured using the caregiver-report version of the Alabama Parenting Questionnaire (APQ; Frick, 1991). The APQ is a 42-item questionnaire with five subscales: positive involvement with children, supervision/monitoring, use of positive discipline techniques, consistency in discipline techniques, and use of corporal punishment. Responses are scored on a five-point Likert scale ranging from 'never' (1) to 'always' (5). APQ total scores range from 42 to 210. We will recode items so that higher scores reflect more positive parenting. The total score will be used for the main analysis and we will perform additional analyses on the separate subscales. We will use the Dutch translation of the APQ (Van Lier & Crijnen, 1999).
2 months
Short Parenting Scale for EMA (SPS-EMA)
Time Frame: 5 hours
Parenting behavior is assessed three times a day during two weeks (at baseline and posttest) with an app for ecological momentary assessment (EMA) using eight adapted items from the Parenting Behavior Inventory (PBI; Lovejoy et al., 1999). For this study, we have selected eight items from the PBI, of which four from each subscale (hostile/coercive and supportive/engaged). The wording of these items has been changed slightly to fit with the EMA format (e.g., 'I say mean things to my child that could make him/her feel bad' becomes 'Since the last notification… I have said mean things to my child that could make him/her feel bad'). We have also changed the response scale from seven- to three-point Likert scale: 'Not true' (1), 'Somewhat true' (2), 'Certainly true' (3). We will analyze the total score of the two subscales combined which ranges from 8-24. For this study, we will call this questionnaire the 'Short Parenting Scale for EMA' (SPS-EMA).
5 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Parenting Sense of Competence Scale (PSOCS)
Time Frame: 2 months
Perceived parenting competence is measured using the Parenting Sense of Competence Scale (PSOCS; Johnston & Mash, 1989). The PSOCS is a 17-item questionnaire comprising two subscales: satisfaction and efficacy. We will use the total score for the main analysis and perform additional analyses on the two subscales. Items are posed as statements (e.g., 'Being a parent makes me tense and anxious'), which are scored for agreement on a six-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (6). PSOCS total scores range from 17 to 102. We will use the Dutch translation of the PSOCS.
2 months
Interpersonal Social Support Evaluation List - 12
Time Frame: 2 months
Parent social support is measured using the abbreviated version of the Interpersonal Social Support Evaluation List (ISEL-12 (72)). The ISEL-12 has 12 items comprising three subscales: appraisal support, belonging support, and tangible support. We will use the total score for our main analysis (research question 4). Items are rated on a four-point scale ranging from 'Definitely false' (1) to 'Definitely true' (4). ISEL-12 total scores range from 12-48, and will be coded so that higher scores indicate more support. The ISEL-12 total score has good psychometric properties (Cohen et al., 1985). We translated the ISEL-12 to Dutch using the back-translation method. We also added two self-made items reflecting aspects of social support we were interested in in light of our intervention: having someone to look after your children (tangible support) and having someone to talk to about worries about your child (appraisal support). These will be analyzed descriptively.
2 months
Strengths and Difficulties Questionnaire - Parent Report (SDQ-P)
Time Frame: 2 months
Child overall psychological problems are measured using parent-report on the Strengths and Difficulties Questionnaire-Parent Report (SDQ-P; Goodman, 1997). The SDQ-P. The SDQ-P comprises five subscales with five items each: hyperactivity/attention deficit, emotional problems, behavioral problems, peer relationship problems, and prosocial behavior. We will use the 'general difficulties' score as our analysis outcome, which aggregates all subscales excluding prosocial behavior (thus comprising 20 items). We will perform additional analyses on the separate subscales. Items are scored on a three-point Likert scale ranging from 'Not true' (0) to 'Certainly true' (2). The 'general difficulties' score ranges from 0-40. We will use the Dutch translation of the SDQ-P (van Widenfelt et al., 2003).
2 months
Child and Adolescent Trauma Screener-Caregiver Report (CATS-C)
Time Frame: 2 weeks
Child PTSD symptoms are measured using parent-report on the Child and Adolescent Trauma Screener-Caregiver Report (CATS-C; Sachser et al., 2017; Dutch translation: Kooij & Lindauer, 2022). The CATS-C starts with 15 yes/no items about child exposure to DSM-5 A-criterion traumatic events. If the parent reports their child has been exposed to at least one of these events, the questionnaire continues with 16 (age 3-6) or 20 (age 7-17) items about PTSD symptoms. Data on PTSD symptoms are thus only collected if the child has experienced at least one A-criterion traumatic event. PTSD symptom items are rated on a four-point Likert scale ranging from 'Never' (0) to 'Almost always' (3). Interference with life domains is assessd with five yes/no items. We will analyze the total symptom score (range: 0-48 for age 3-6; 0-60 for age 7-17). We will perform additional analyses on the separate subscales. Scores on trauma exposure items will be reported descriptively.
2 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD Checklist for DSM-5
Time Frame: 1 month
PTSD symptoms are measured at baseline using the PTSD Checklist for DSM-5 (PCL-5; Blevins et al., 2015). The PCL-5 comprises 20 items describing PTSD symptoms rated on a five-point Likert scale ranging from 'Not at all' (0) to 'Extremely' (4). The PCL-5 comprises four subscales corresponding to DSM-5 PTSD symptom clusters (intrusion, avoidance, negative alterations in mood and cognitions, and hyperarousal). We will use the PCL-5 total score (ranging from 0-80) as a moderator variable. We will use the Dutch translation of the PCL-5 (Boeschoten et al., 2014).
1 month
Life Events Questionnaire for DSM-5 (LEC-5)
Time Frame: Lifetime
Trauma exposure is measured at baseline using the Life Events Questionnaire for DSM-5 (LEC-5; Weathers et al., 2013). The LEC-5 comprises 17 items which describe DSM-5 A-criterion traumatic events (e.g., 'Fire or explosion'). Participants note for each event on a scale with 6 options whether they were directly or indirectly (i.e., as a witness, learning about it happening to someone close to them, or as part of their job) exposed to it. In case of multiple trauma exposures, the participant is asked to indicate which event bothers them the most. This event is called the 'index trauma' and will be used to determine trauma type in this study. The Dutch translation of the LEC-5 is used (Boeschoten et al., 2014).
Lifetime
Outcome Questionnaire-45 (OQ-45)
Time Frame: 1 week
General psychosocial functioning is measured as part of the ROM at Arkin using the Outcome Questionnaire-45 (OQ-45; Lambert et al., 1996). We will use the closest ROM measurement before baseline. The OQ-45 comprises 45 items, divided into three subscales: symptom distress (25 items, measures symptoms of depression, anxiety and substance abuse), interpersonal relations (11 items, measures relational functioning) and social role (9 items, measures functioning in school, work and/or leisure). Items are scored on a 5-point Likert scale ranging from 'Never' (0) to 'Always' (4). We will descriptively report the OQ-45 total score, which ranges from 0-180.
1 week
Demographic information
Time Frame: Lifetime
To provide information on the demographic background of the sample, participants complete a short demographic questionnaire (DQ) at baseline with items about themselves and their children.
Lifetime
Intervention adherence and satisfaction
Time Frame: 10 weeks
For participants in the intervention condition, results on intervention adherence (completion of online modules; attendance of face-to-face sessions; and use of PTSD-specific content in the online library) will be reported descriptively. Furthermore, intervention group participants complete a short satisfaction questionnaire (SQ) at posttest. The SQ contains closed-ended and open-ended questions on aspects of the intervention, and invites participants to provide suggestions for improvement. Results will be reported descriptively in the publication of the current study and will be used for future improvement of the intervention.
10 weeks
Short Form PTSD Checklist for DSM-5 (SF-PCL-5)
Time Frame: 5 hours
PTSD symptoms are assessed in the EMA app using a short-form version of the PTSD Checklist for DSM-5 (PCL-5) with one item for each of the four symptom clusters (SF-PCL-5; Zuromski et al., 2019). Each item is rated for past-month frequency on a five-point Likert scale ranging from 'Not at all' (0) to 'Extremely' (4). The instruction of the SF-PCL-5 will be changed to fit with the EMA format. That is, participants are asked to report on their symptoms during the current part of the day (morning/afternoon/evening). Scores range from 0-16.
5 hours
Sleep Quality Rating
Time Frame: 1 day
Sleep quality will only be assessed in the morning EMA assessments, using a single item ('How well did you sleep last night?') answered on a 10-point scale.
1 day
Situational Context
Time Frame: 5 hours
To assess the situational context, each EMA questionnaire starts with two situation items (Where are you; Who are you with), answered using multiple choice.
5 hours
Distress Rating
Time Frame: 5 hours
To assess current levels of distress, each EMA questionnaire contains a single item ('How much distress are you currently feeling?'), answered on a 10-point scale.
5 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Kathleen Thomaes, Sinai Centrum

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

February 3, 2022

First Submitted That Met QC Criteria

February 11, 2022

First Posted (Actual)

February 14, 2022

Study Record Updates

Last Update Posted (Actual)

February 1, 2024

Last Update Submitted That Met QC Criteria

January 31, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

After completion of the study, metadata will be made available. Anonymized IPD can be requested by submitting a data request form to the investigators. IPD will only be shared for those participants who provided informed consent for this in advance.

IPD Sharing Time Frame

Anticipated in 2025, for at least 15 years.

IPD Sharing Access Criteria

Data request form

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post-traumatic Stress Disorder

Clinical Trials on KopOpOuders-PTSD

Subscribe